GH Research (GHRS) Current Assets (2021 - 2026)
GH Research (GHRS) posted quarterly Current Assets of $286.0 million for Q4 2025, up 85.43% year-over-year from $154.2 million in Q4 2024, and down 2.99% quarter-over-quarter from $294.8 million in Q3 2025.
GH Research (GHRS) Current Assets (2021 - 2026) Analysis & Trends
GH Research's Current Assets history runs 5 years deep, the most recent figure standing at $286.0 million for Q4 2025.
- In Q4 2025, Current Assets rose 85.43% year-over-year to $286.0 million; the TTM figure through Dec 2025 stood at $286.0 million (up 85.43% YoY), while the FY2025 annual figure was $286.0 million, up 85.43% from the prior year.
- Current Assets for Q4 2025 stood at $286.0 million, down from $294.8 million in the prior quarter.
- The five-year high for Current Assets was $294.8 million in Q3 2025, with the low at $152.9 million in Q2 2024.
- The 5-year median for Current Assets is $167.5 million (2022), against an average of $215.1 million.
- The sharpest annual moves came in 2023 and 2025: Current Assets sank 39.77% in 2023, then surged 92.19% in 2025.
- GH Research's Current Assets stood at $166.0 million in 2021, then grew by 1.51% to $168.5 million in 2022, then dropped by 2.64% to $164.1 million in 2023, then declined by 6.01% to $154.2 million in 2024, then jumped by 85.43% to $286.0 million in 2025.
- Business Quant data shows GHRS's Current Assets at $286.0 million in Q4 2025, $294.8 million in Q3 2025, and $293.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 368.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 368.82 Mn |
| Dec 31, 2025 | 285.98 Mn |
| Sep 30, 2025 | 294.79 Mn |
| Jun 30, 2025 | 293.88 Mn |
| Mar 31, 2025 | 294.67 Mn |
| Dec 31, 2024 | 154.23 Mn |
| Sep 30, 2024 | 154.95 Mn |
| Jun 30, 2024 | 152.91 Mn |
| Mar 31, 2024 | 160.48 Mn |
| Dec 31, 2023 | 164.09 Mn |
| Sep 30, 2023 | 164.04 Mn |
| Jun 30, 2023 | 166.40 Mn |
| Mar 31, 2023 | 164.72 Mn |
| Dec 31, 2022 | 168.54 Mn |
| Sep 30, 2022 | 260.04 Mn |
| Jun 30, 2022 | 266.23 Mn |
| Mar 31, 2022 | 273.46 Mn |
| Dec 31, 2021 | 166.03 Mn |
| Sep 30, 2021 | 285.56 Mn |